uniQure announces successful NASDAQ IPO - Gilde Healthcare

uniQure announces successful NASDAQ IPO

6 februari 2014

Amsterdam, The Netherlands – uniQure, a Gilde Healthcare portfolio company, announced the pricing of its initial public offering of 5,400,000 ordinary shares at an initial public offering price of $17.00 per ordinary share raising $91.8 million and started trading under the symbol “QURE” on the NASDAQ Global Select Market on February 5, 2014. uniQure has granted the underwriters a 30-day option to purchase up to an additional 810,000 ordinary shares from uniQure at the public offering price, less underwriting discounts. After deducting the underwriting discounts and other estimated offering expenses payable by uniQure, the net proceeds of the initial public offering are expected to be approximately $81.9 million.
 
Proceeds of the initial public offering will be used for the commercialization of  Glybera® and further clinical development of uniQure’s product pipeline consisting of gene therapies for the treatment of Hemophilia B, Acute Intermittent Porphyria, Sanfilippo B Syndrome and Parkinson’s Disease.
 
Edwin de Graaf represented Gilde Healthcare on the company’s supervisory board and has worked closely with management to support the company’s corporate development since 2006. In this period the company built a platform to rapidly develop and manufacture gene therapies and received regulatory approval for Glybera®, the first gene therapy approved by the European Commission. 

About uniQure
uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. uniQure has developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders. The approach is validated by multiple partnerships and the regulatory approval of lead product Glybera®. www.uniqure.com

About Gilde Healthcare
Gilde Healthcare (Utrecht, The Netherlands and Cambridge, USA) is a transatlantic growth capital investor focused on private healthcare companies. It has over €450 million ($600 million) under management and is actively looking to lead new investments in therapeutics, medical devices and healthcare services. For a list of Gilde’s portfolio companies please visit the website at www.gildehealthcare.com.

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
23 september 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
12 september 2022

Gilde Healthcare Company Volta Medical publishes clinical results on AI based solution for patients in atrial fibrillation

Volta Medical, a pioneering health tech company developing artificial intelligence (AI) software solutions to assist electrophysiologists to treat cardiac arrhythmias, announced that the Journal of Cardiovascular Electrophysiology (JCE) has published peer-reviewed results from the Company’s...
2 september 2022